| Autor: |
Stewart VA; Division of Malaria Vaccine Development, Walter Reed Army Institute of Research, Silver Spring, MD, USA. Ann.stewart@na.amedd.army.mil, McGrath SM, Dubois PM, Pau MG, Mettens P, Shott J, Cobb M, Burge JR, Larson D, Ware LA, Demoitie MA, Weverling GJ, Bayat B, Custers JH, Dubois MC, Cohen J, Goudsmit J, Heppner DG Jr |
| Jazyk: |
angličtina |
| Zdroj: |
Infection and immunity [Infect Immun] 2007 May; Vol. 75 (5), pp. 2283-90. Date of Electronic Publication: 2007 Feb 16. |
| DOI: |
10.1128/IAI.01879-06 |
| Abstrakt: |
The RTS,S/AS02A protein-based vaccine consistently demonstrates significant protection against infection with Plasmodium falciparum malaria and also against clinical malaria and severe disease in children in areas of endemicity. Here we demonstrate with rhesus macaques that priming with a replication-defective human adenovirus serotype 35 (Ad35) vector encoding circumsporozoite protein (CS) (Ad35.CS), followed by boosting with RTS,S in an improved MPL- and QS21-based adjuvant formulation, AS01B, maintains antibody responses and dramatically increases levels of T cells producing gamma interferon and other Th1 cytokines in response to CS peptides. The increased T-cell responses induced by the combination of Ad35.CS and RTS,S/AS01B are sustained for at least 6 months postvaccination and may translate to improved and more durable protection against P. falciparum infection in humans. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
